Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

925
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
925
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

4.1K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Health care systems that harm.

Australian nursing & midwifery journal·2018
Same journal

Specialty Competencies for Nurse Practitioners.

Australian nursing & midwifery journal·2018
Same journal

Specialist nursing role to address poor physical health.

Australian nursing & midwifery journal·2018
Same journal

Developing acute mental health services in Perth.

Australian nursing & midwifery journal·2018
Same journal

Awareness building of sexual health concerns.

Australian nursing & midwifery journal·2018
Same journal

Hold my hand and walk with me: Empathy on the mental health inpatient unit.

Australian nursing & midwifery journal·2018
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

7.0K

HOPE FOR PKU. FUTURE.

Justine Inglis

    Australian Nursing & Midwifery Journal
    |December 14, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Living with Phenylketonuria (PKU) for 45 years presents unique challenges, primarily due to societal views and limited awareness of this genetic disorder. Improving public understanding of PKU is crucial for those affected.

    More Related Videos

    Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
    07:35

    Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

    Published on: June 23, 2015

    12.0K
    Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
    09:54

    Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

    Published on: November 4, 2018

    8.6K

    Related Experiment Videos

    Last Updated: Feb 17, 2026

    Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
    11:20

    Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

    Published on: May 12, 2020

    7.0K
    Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
    07:35

    Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

    Published on: June 23, 2015

    12.0K
    Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
    09:54

    Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

    Published on: November 4, 2018

    8.6K

    Area of Science:

    • Metabolic disorders
    • Genetics
    • Public health

    Background:

    • Phenylketonuria (PKU) is a rare inherited metabolic disorder.
    • Long-term management of PKU requires significant patient adherence and support.
    • Societal perception and awareness significantly impact the quality of life for individuals with chronic conditions.

    Purpose of the Study:

    • To highlight the personal challenges faced by individuals living with Phenylketonuria (PKU) for an extended period.
    • To underscore the impact of societal views and lack of awareness on the PKU community.
    • To advocate for increased public understanding and support for rare genetic disorders like PKU.

    Main Methods:

    • This study is based on a 45-year personal experience of living with Phenylketonuria.
    • Qualitative reflection on the lived experiences and challenges encountered.
    • Analysis of the interplay between personal health management and societal factors.

    Main Results:

    • Individuals with Phenylketonuria (PKU) face significant challenges beyond the metabolic aspects of the disease.
    • Societal misunderstanding and lack of awareness create additional burdens for patients.
    • A 45-year perspective reveals persistent issues related to public perception of PKU.

    Conclusions:

    • Increased public awareness and education are essential to improve the lives of individuals with Phenylketonuria (PKU).
    • Addressing societal views can alleviate the psychosocial challenges associated with rare genetic disorders.
    • Further research into patient-reported outcomes and social determinants of health in PKU is warranted.